Adverse effects of the atypical antipsychotics

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 12, 1998, Pages 17-22

  Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; ERYTHROMYCIN; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; HALOPERIDOL; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; VALPROIC ACID;

AGRANULOCYTOSIS; COGNITIVE DEFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HUMAN; LIVER TOXICITY; OBESITY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PSYCHOSIS; QT INTERVAL; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA;

AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CENTRAL NERVOUS SYSTEM DISEASES; CLOZAPINE; DIBENZOTHIAZEPINES; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; HEALTH STATUS; HUMANS; HYPOTENSION, ORTHOSTATIC; PIRENZEPINE; QUALITY OF LIFE; RECEPTORS, CHOLINERGIC; RISPERIDONE; SCHIZOPHRENIA; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SLEEP DISORDERS; TREATMENT REFUSAL; WEIGHT GAIN;

EID: 0031719842     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Collaborative Working Group on Clinical Trial Evaluations. Assessment of EPS and tardive dyskinesia in clinical trials. J Clin Psychiatry 1998; (suppl 12):23-27
2. Snyder S, Greenberg D, Yamamura H. Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 1974;31:58-61
3. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull 1997;23:567-582
4. Beasley CM Jr, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(suppl 10):13-17
5. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15 (suppl 1):36S-44S
6. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
8. Peuskens J and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726
9. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997;54:549-557
10. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154: 1248-1254
11. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-211
12. Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997;154:782-791
13. Jibson MD, Tandon R. The newer atypical antipsychotics. J Psychiatr Res. In press
14. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine/benztropine. Arch Gen Psychiatry 1988;45:789-796
15. 2 pKi values. J Pharmacol Exp Ther 1989;251:238-246
16. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
17. 2 receptors. Psychopharmacology (Berl) 1993;112(suppl 1):S40-S54
18. Moore NA, Calligaro DO, Wong TD, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2: 281-293
19. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993;112:285-292
20. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995;275:101-113
21. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58(suppl 10):55-62
22. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371
23. Meltzer HY, Ranjan R. Valproic acid treatment of clozapine-induced myoclonus [letter]. Am J Psychiatry 1994;151:1246-1247
24. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1998
25. Beasley CM Jr, Tollefson GD, Tran PV, et al. Olanzapine vs placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123
26. Daniel DG, Goldberg TE, Weinberger DR, et al. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 1996;153:417-419
27. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996;16:158-169
28. Hamner MB, Silber C, Driscoll R, et al. Cardiovascular safety of sertindole. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR 575:223
29. Sramek JJ, Mack RJ, Awni W, et al. Two rapid-dose titrations of sertindole in patients with schizophrenia. J Clin Psychopharmacol 1997;17:419-422
30. Brecher MB, Lemmens P, van Baelen B. Tolerability and cardiovascular safety of risperidone. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR 612:233
31. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418
32. Tandon R. Cholinergic aspects of schizophrenia. Br J Psychiatry. In press.
33. Parada MA, Hernandez L, Puig de Parada M, et al. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J Pharmacol Exp Ther 1997;281:582-588
34. Kane JM, Casey DE, Daniel DG, et al. Antipsychotic agents: minimizing side effects to maximize compliance. J Clin Psychiatry Intercom; October
35. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding Psychopharmacology (Berl) 1996;124:57-73
36. Daniel DG, Whitcomb SR. Treatment of the refractory schizophrenic patient. J Clin Psychiatry 1998;59(suppl 1):13-19
37. van Kammen DP, McEvoy JP, Targum S, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl) 1996;124:168-175
38. Milner K, Tomori O, Florence T, et al. Psychotropic medications and sexual dysfunction. In: Buckley PF, ed. Sexuality Among Patients With Serious Mental Illness. Washington, DC: American Psychological Association Press; 1998
39. Friedman S, Harrison G. Sexual histories, attitudes, and behavior of schizophrenic and normal women. Arch Sex Behav 1984;14:555-567
40. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, et al. Sexualdys unction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-141
41. Goldstein JM. Preclinical profile of Seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Holliday SG, Ancill RJ, MacEwan GW, eds. Schizophrenia: Breaking Down the Barriers. New York, NY: John Wiley & Sons; 1996:177-208
42. Kleinberg D, Brecher MB, Davis JM. Prolactin levels and adverse events in patients treated with risperidone. In: New Research Program and Abstracts of the 150th Annual Meeting of the American Psychiatric Association; May 21, 1997; San Diego, Calif. Abstract NR 599:229
43. Kopala LC. Clinical experience in developing treatment regimens with the novel antipsychotic risperidone. Int Clin Psychopharmacol 1997;12(suppl 4):S11-S18
44. Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand Suppl 1996;389:12-17
45. Kirkegaard A, Jensen A. An investigation of some side effects in 47 psychotic patients during treatment with clozapine and discontinuing of the treatment. Arzneimittelforschung 1979;29:851-858
46. Naber D, Leppig M, Grohmann R, et al. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia: a retrospective study of 387 patients. Psychopharmacology (Berl) 1989;99: S73-S76
47. Dorta G, Siebenmann R, Frohli P, et al. Clozapin-induzierter cholestatischer ikterus: ein fallbericht. Z Gastroenterol 1989;27:388-390
48. Gupta S, Masand PS. Olanzapine: review of its pharmacology and indications in clinical practice. Prim Psychiatry 1997;4:73-82
49. Marder SR. Clinical experience with risperidone. J Clin Psychiatry 1996; 57(suppl 9):57-61
50. Kane JM, Schizophrenia. N Engl J Med 1996;334:34-41
51. Gerson SL, Lieberman JA, Friedenberg WR, et al. Polypharmacy in fatal clozapine-associated agranulocytosis [letter]. Lancet 1991;338:262-263
52. Alphs LD, Meltzer HY, Bastani B, et al. Side effects of clozapine and their management. Pharmacopsychiatry 1991;24:46
53. Malhotra AK, Litman RE, Pickar D. Adverse effects of antipsychotic drugs. Drug Saf 1993;9:429-436
54. Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994;55(9, suppl B):137-138
55. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137
56. Flynn SW, Altman S, MacEwan GW, et al. Prolongation of clozapine-induced granulocytopenia associated with olanzapine [letter]. J Clin Psychopharmacol 1997;17:494-495
57. Love RC, Levin GM, Richards AL, et al. Current trends in the use of novel antipsychotics. J Clin Psychiatry Intercom; April 1, 1997